We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-2.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.7B
AUM Growth
-$733M
Cap. Flow
+$511M
Cap. Flow %
4.78%
Top 10 Hldgs %
33.24%
Holding
188
New
39
Increased
39
Reduced
24
Closed
30

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$452M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$186M
3
CMMB
Chemomab Therapeutics
CMMB
+$128M
4
HAE icon
Haemonetics
HAE
+$105M
5
IRON icon
Disc Medicine
IRON
+$86.6M

Top Sells

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$369M
2
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$319M
3
PFE icon
Pfizer
PFE
+$133M
4
BIIB icon
Biogen
BIIB
+$121M
5
CNC icon
Centene
CNC
+$120M

Sector Composition

Rank Sector Weight
1 Healthcare 94.88%
2 Technology 0.12%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
126
Nuvation Bio
NUVB
$2.31B
$8.36M 0.08%
+800,000
New +$8.94M
OTIC
127
DELISTED
Otonomy, Inc.
OTIC
$8.29M 0.08%
3,250,000
– –
STRO icon
128
Sutro Biopharma
STRO
$390M
$7.97M 0.07%
35,000
– –
NBTX
129
Nanobiotix
NBTX
$1.9B
$7.52M 0.07%
500,000
– –
SYBX
130
DELISTED
Synlogic
SYBX
$7.27M 0.07%
135,333
– –
TARA icon
131
Protara Therapeutics
TARA
$216M
$7.08M 0.07%
450,000
– –
WHWK
132
Whitehawk Therapeutics
WHWK
$183M
$6.7M 0.06%
346,263
– –
SGFY
133
DELISTED
Signify Health, Inc.
SGFY
$6.58M 0.06%
+225,000
New +$6.96M
LABP
134
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$6.56M 0.06%
+68,100
New +$8.89M
NTLA icon
135
Intellia Therapeutics
NTLA
$1.54B
$5.82M 0.05%
+72,500
New +$4.87M
LUNG icon
136
Pulmonx
LUNG
$53.6M
$5.72M 0.05%
125,000
– –
OBIO icon
137
Orchestra BioMed
OBIO
$232M
$5.59M 0.05%
500,000
– –
TCRR
138
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$5.5M 0.05%
249,279
– –
FBRX icon
139
Forte Biosciences
FBRX
$1.57B
$5.47M 0.05%
6,387
+2,699
+73% +$2.21M
DYN icon
140
Dyne Therapeutics
DYN
$4.17B
$5.44M 0.05%
350,000
– –
INNV icon
141
InnovAge Holding
INNV
$1.58B
$5.16M 0.05%
+200,000
New +$4.93M
ADAG
142
Adagene
ADAG
$254M
$4.94M 0.05%
+275,000
New +$6.26M
LBPH
143
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$4.91M 0.05%
+300,000
New +$4.9M
SBBP
144
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.82M 0.05%
1,744,669
-1,744,700
-50% -$5.26M
CMPS
145
Compass Pathways
CMPS
$1.5B
$4.71M 0.04%
127,816
-222,184
-63% -$9.74M
RXDX
146
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$4.57M 0.04%
+250,000
New +$5.16M
IFRX icon
147
InflaRx
IFRX
$252M
$4.15M 0.04%
1,064,118
+508,093
+91% +$2.6M
AXSM icon
148
PUT
Axsome Therapeutics
AXSM
$11.8B
$2.83M 0.03%
+50,000
New +$3.52M
LAB icon
149
CALL
Standard BioTools
LAB
$344M
$2.26M 0.02%
+500,000
New +$2.75M
SANA icon
150
Sana Biotechnology
SANA
$888M
$2.01M 0.02%
+60,000
New +$1.95M
4 5
6
7 8

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2021 Portfolio in Review

As of Q1 2021, OrbiMed held 188 positions worth $10.7B, down 6.4% from $11.4B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed deployed $511M of net new capital in Q1 2021, opening 39 new positions and adding to 39 existing holdings. Its largest new stake was Edgewise Therapeutics: 13,944,680 shares worth $453M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Prelude Therapeutics, an estimated $369M trimmed.

  • OrbiMed's largest Q1 2021 buy was Edgewise Therapeutics: 13,944,680 shares worth $453M.
  • OrbiMed added most to Merck in Q1 2021, an estimated $83M increase.
  • OrbiMed's biggest Q1 2021 reduction was Prelude Therapeutics, cutting an estimated $369M.
  • OrbiMed fully exited Prevail Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $319M.
  • OrbiMed's ten largest holdings make up 33% of its $10.7B portfolio in Q1 2021.
  • OrbiMed opened 39 new positions and closed 30 in Q1 2021.
  • OrbiMed's portfolio value fell 6.4% quarter-over-quarter to $10.7B.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.